Wockhardt shares rise 10% after Zaynich aids successful liver transplant trial
Wockhardt's shares surged 8.6% after its antibiotic Zaynich successfully treated a US cancer patient, enabling a liver transplant and chemotherapy. The drug is nearing Phase III trials for global approval.
Site référencé: The Economic Times
The Economic Times
EM stocks rally as Alibaba surges on AI revenue boost
2/09/2025
How will new expiry days impact derivatives market ?
2/09/2025
Indian equities back in the green on improved GDP show
2/09/2025
Auto stocks rise up to 6% ahead of GST council meeting. Tata Motors, Maruti, M&M defy weak August sales
1er/09/2025
SBI Contra Fund, ICICI Prudential Value Fund among 5 funds with high cash holding
1er/09/2025
Largecaps bear the brunt as FIIs reduce stakes across markets in June quarter
1er/09/2025
